Regarding to histoscores of Oct-4 staining, there was prominent discrepancy between adenocarcinoma and squamous Anlotinib solubility dmso cell carcinoma (39.40 ± 3.59 and 21.64 ± 2.47, p = 0.008). There was significant association of Oct-4 histoscores among well, moderated, and poor differentiation of tumor (15.69 ± 3.70, 24.27 ± 2.73, and 43.80 ± 3.49, p = 0.039), and quantification of Selleck NCT-501 staining also revealed that these associations differed markedly in adenocarcinoma or squamous cell carcinoma population (Figure 1H). There were no associations between Oct-4 expression and malignant local advance, lymph node metastasis,
or TNM stage of disease (Figure 1I). Figure 1 Oct-4 expression in tissues of well-differentiated adenocarcinoma (A), well-differentiated squamous cell carcinoma (B), poorly
differentiated adenocarcinoma (C), and poorly differentiated squamous cell carcinoma (D), as well as VEGF staining (E) and MVD staining Trichostatin A cell line (F) were demonstrated immunohistologically. Quantification of Oct-4 expression (Oct-4 histoscore) with respect to differentiation status or tumor histology (G) and local advance or lymph nodes metastasis (H) is shown; 95% CIs are indicated. Oct-4 expression in NSCLC cell lines To better understand the expression status of Oct-4 in NSCLC, we examined the expression of Oct-4 in the NSCLC cell lines, A549, H460, and H1299. Oct-4 mRNA was detected in each of these cell lines (Figure 1G). Association of Oct-4 expression with malignant proliferation according to differences in VEGF-mediated angiogenesis Intratumoral Ki-67 expression, a marker
of malignant proliferation, varied according to Oct-4 phenotype in the population Selleck Rucaparib under study, with high Ki-67 expression showing a significant association with positive Oct-4 staining (Table 1). Quantification of staining revealed that this association differed markedly depending on Oct-4 histoscores (Figure 2A, p = 0.001) and showed that these two markers were positively correlated (Figure 2B). In MVD-negative and VEGF-negative subsets, intratumoral Ki-67 expression varied significantly according to Oct-4 phenotype (Figure 2A); Ki-67 (Figure 2C) and Oct-4 (Figure 2E) expression were also positively correlated in these subsets. These results suggest a prominent association of Oct-4 expression with malignant proliferation in NSCLC, especially in cases with weak VEGF-mediated angiogenesis. Figure 2 Ki-67 expression histoscores were significantly different (ANOVA) according to different Oct-4 status in all cases, and in subsets of MVD-negative, MVD-positive, VEGF-negative, and VEGF-positive cases ( A ). All cases were divided into positive (above the median histoscore) and negative (below the median histoscore) groups. The association of Oct-4 staining with Ki-67 expression was positive in all cases (B), and in subsets of MVD-negative (C), MVD-positive (D), VEGF-negative (E), and VEGF-positive (F) cases.